Probiodrug's pGlu-Abeta Approaches being presented
at 14th AAT Symposium on Advances in Alzheimer Therapy
The Symposium will be held from 9
to 12 March 2016 at the
Athens Hilton in Athens, Greece
HALLE/SAALE, Germany, 09 March 2016
- Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical
company developing novel therapeutic solutions to treat Alzheimer's
disease, announces today that Prof Dr Cynthia A. Lemere and Prof Dr
Hans-Ulrich Demuth will be presenting at the 14th International
Athens/Springfield Symposium on Advances in Alzheimer Therapy (AAT)
in Athens, Greece.
Prof Dr Hans-Ulrich Demuth will hold a
presentation entitled "The pyroglutamate
modification of toxic A-beta resulted in new therapeutic
approaches: Inhibitors of glutaminyl cyclase and highly specific
antibodies - A status report" on Friday, 11 March 2016 in Room
Hesperides at 8:50 am EET.
Hans-Ulrich Demuth co-founded
Probiodrug and is a member of the company's Scientific Advisory
Board. He worked for several years as Chief Scientific Officer at
Probiodrug on the molecular mechanisms of Alzheimer's disease and
laid the scientific ground for Probiodrug's currently pursued
targets. Hans-Ulrich Demuth is Head of the Department of Drug
Design and Target Validation at the Fraunhofer Institute for Cell
Therapy and Immunology IZI.
Prof Dr Cynthia Lemere's presentation entitled
"Phagocytic characterization and therapeutic
efficacy of an Anti-PyroGlutamate-3 A-beta IgG2a antibody in aged
APP/PS1dE9 mice" will be held on Saturday, 12 March 2016 in
Room Terpsichore at 12:00 pm EET.
Cynthia
Lemere is a Scientist at the Brigham and Women's Hospital and
Associate Professor of Neurology at the Harvard Medical School,
Boston, USA. She is a member of the Scientific Advisory Board of
Probiodrug and she and her team authored a number of papers
describing the preclinical effects of Probiodrug's anti-pGlu-Abeta
Antibody as a result of an extended collaboration.
Inge Lues, Chief Development Officer of
Probiodrug, stated: "We are extremely happy about our
collaboration with Cynthia Lemere, who has applied her expertise in
AD pathology to our programme and particularly her knowledge on the
aspect of monoclonal Abeta antibody as therapeutic target."
###
For more information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 20 7862 6475
Email: probiodrug@humebrophy.com
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam:
PBD) is a biopharmaceutical company focused on the development of
new therapeutic products for the treatment of Alzheimer's
disease.
Founded
in 1997, the company successfully developed a novel therapeutic
concept for diabetes - the DP4 inhibitors - which provided the
basis for a novel class of antidiabetics - the gliptins. Its core
capabilities are based on its long-standing expertise in the
elucidation of the structure and function of enzymes involved in
the modification of proteins and peptides, which play a central
role in pathological conditions.
Today
Probiodrug's aim is to become a leading company in the development
of Alzheimer's disease treatments and to thereby provide a better
life for Alzheimer's disease patients. It has identified a new
therapeutic concept linked to disease initiation and progression.
The development approaches are targeting pyroglutamate-Abeta
(pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's
disease. The Company has medical use and composition of matter
patents related to the inhibition of Glutaminyl Cyclase (QC) and
anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in
the Company's view, with a leading position in this field of
research.
www.probiodrug.de
About Alzheimer's disease
Alzheimer's disease is a neurological disorder, which is the most
common form of dementia, and ultimately leads to death. Because
Alzheimer's disease cannot be cured and is degenerative, the
affected patients must increasingly rely on others for assistance.
Today, over 46 million people worldwide currently live with the
condition and this number is expected to increase to 132 million by
2050. Alzheimer's also has an estimated, global societal cost of
US$ 818 billion (World Alzheimer Report 2015).
Forward Looking Statements
Information set forth in this press release
contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained
herein represent the judgment of Probiodrug AG as of the date of
this press release. Such forward-looking statements are neither
promises nor guarantees, but are subject to a variety of risks and
uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change
in our expectations or any change in events, conditions or
circumstances on which any such statement is based.